messag provid preview beyond large-cap
pharmaceut compani fake news look tremend
coverag univers contain small- mid- large-cap compani one underli
theme immune-oncolog believ immune-oncolog major growth driver
pharma/biotech world whichev compani best player challeng arena
see strong growth previous publish io outlook earlier
year see note januari contain potenti upcom catalyst scientif
rational respect outcom thu preview individu compani
affect think competit landscap present well futur
oncolog play field preview understood
read togeth tri come coher invest hypothesi
touch three compani see hypothesi root biolog
clinic trial result pipelin product also light balanc sheet recent tax
reform believ built barrier entri around covet
cancer indic suitabl inhibit lung melanoma head neck
cancer kidney bladder barrier constantli reinforc increas
height numer trial readout mono- combin therapi make market
entri difficult compani despit load pipelin rich catalyst
howev note undertak great effort find optim combin
io space
differenti pfe io pipelin see least near-term
similar jnj io pipelin seem similar
thu potenti circumv barrier entri also near-
term perhap even io underdog term near-term growth io
opinion still remain behind could chang expand
indic jnj main pressur exist hematolog product may come car-
compani long-term howev seem think far ahead io
game develop off-the-shelf car-t pfe stake cellecti cll
bispecif antibodi cell engag compani bispecif come
collabor genmab gmxay bispecif come
focu oncolog sale verzenio cyramza
view recent launch success see growth potenti especi verzenio
expect label expans yet lli focu clearli oncolog diabet
immunolog trulic baricitinib dynam competit landscap
lli diabet franchis given recent competitor approv decis factor lli
biggest busi expect price strategi lli rewind studi crucial
determin compani gain lose market share impress
olumi launch germani repetit depend view
anticip fda approv also label compar eu label label without
warn exampl thromboembol event german label contain warn
patient present prior deep vein thrombosi pulmonari embol howev
warn highlight among list warn believ event
import want achiev revenu compound-annual-growth-rate two late stage
product immunolog believ humira remain workhors
compani need find new cash-gener franchis biosimilar eros
competit alreadi approv non-tnf drug becom seriou problem continu
consid compani lag behind oncolog large-
cap compani tri increas footprint space anticip
launch rova-t late see commerci opportun sclc
insuffici line indic expans develop commerci
may still insuffici replac humira new workhors quick fix abbv
problem could acquisit mid-cap biotech promis io portfolio
page analyst certif import disclosur
page analyst certif import disclosur
 maintain buy rate due posit outlook
long-term growth potenti opdivo
squar investor focu bmi expect readout part
squ /non-squ nsclc compris three distinct trial part
part part complet enrol previous provid
extens analysi think may success across three
subtrial uncertainti revolv around success io combin
patient opinion direct read-through nonsignific
astrazeneca azn mystic transcend rather simplist notion vs
vs trial design dose schedul see previou note essenc
believ crucial structur bind differ yervoy
tremelimumab may translat clinic distinct outcom opinion key
commerci success opdivo/yervoy whether os benefit superior
blockad plu chemotherapi intermediate/high expressor cohort
potenti cut-off expect all-com portion part
similar time approv base may crucial
commerci success sinc alreadi approv nsclc question
much share captur second market acknowledg
roch rhhbi like get approv nsclc base data
question becom whether data competit enough comparison
pressur merck may come high express keytruda
monotherapi show mpf month opdivo plu yervoy
show initi mpf month posit patient mpf reach
high express result suggest opdivo plu yervoy might
clinic superior keytruda monotherapi could expect biolog
question remain good os benefit opdivo plu yervoy
express assum cutoff could take market share
keytruda plu chemotherapi segment staunch believ neither
patient physician want use chemotherapi opdivo plu yervoy show suffici
efficaci unfortun detail enough preliminari data
believ io combin could come close enough io plu chemotherapi
combin point unsur io combin may better io
chemotherapi combin neg patient clear cellular rational
support notion howev point evalu opdivo plu
chemotherapi all-com patient popul assum similar
continu see readout essenti buy hypothesi
media report barron believ readout could motiv make move
especi manag commentari call concern acquisit
io space
believ tumor mutat burden tmb may lead way futur clinic
trial hypothes retrospect analysi like prospect
one believ concept tmb still question address
point understand studi chemo follow
opdivo plu yervoy includ tmb prospect analysi although rule
tmb analysi point employ two cycl
page analyst certif import disclosur
chemotherapi might suffici releas neoantigen success io
combin therapi believ burden impos patient chemotherapi would
greatli reduc treatment algorithm may prefer physician
patient alik alreadi seen promis initi clinic data use approach
beyond opportun nsclc expect opdivo growth beyond base
current indic base indic mostli except melanoma howev
readout next two year could propel opdivo alon combin
approv rcc liver gastric cancer furthermor new dose schedul
approv indic expect pdufa date march believ could
increas opdivo share academ commun set due monthli dose
per compani opdivo rapidli becom soc liver cancer
receiv approv addit expect continu growth opdivo europ
nsclc withdrawn submiss base
continu penetr indic
develop melanoma rcc parpi
bmi clinic develop io refractori melanoma patient treat relatlimab
opdivo promis base result present esmo
strikingli patient present data refractori
opdivo/yervoy combin make patient difficult treat opinion
success relatlimab stun expans cohort compris patient
underway could view basi regulatori submiss data
look good enough expans cohort enrol patient
believ patient could use control arm clearli seem
interest develop biomark inhibitor space present
promis result howev learn anyth regard baselin
liver metastasi one take home messag data may
solut everi cancer type cervic cancer data show improv
respons use io combin approach nevertheless bmi inhibitor
could best-in-class base preclin data once-daili dose also
clinic trial collabor inci inhibitor epacadostat expect readout
inci instrument understand bmi
inhibitor furthermor interest piqu ph trial set begin earli
evalu combin opdivo rubraca mainten treatment ovarian
cancer tnbc trial direct competit tesaro tsro
effort set use zejula keytruda addit
evalu opdivo plu yervoy vs sutent reach signific os intermediate-
poor-risk rcc patient qualiti combo efficaci underpin
complet respons rate durat respons yet data also highlight certain
shortcom subgroup analysi show combo benefit
patient led trial miss endpoint patient pdufa date set
april eu approv could potenti come
page analyst certif import disclosur
believ eliqui signific growth driver base best-in-class
profil eliqui noac demonstr superior vs warfarin nonvalvular
atrial fibril accord manag noac penetr continu
consider room grow continu eros warfarin eliqui number one
noac share vs xarelto predaxa remind nbrx brand share
eliqui
base deliber believ strong growth potenti opdivo
eliqui sale estim opdivo nsclc rcc
respect
sourc compani report bloomberg intellig
made adjust model base chang revenu estim driven
script trend key product modestli increas estim
oper margin beyond base manag commentari regard
margin growth rate competitor confer earlier month adjust
revenu estim remain revenu
estim respect
ep estim move subsequ year
ep estim slightli increas
valuat risk
valuat maintain price target base dcf analysi use
unchang wacc lt growth rate import
trial readout horizon offer multipl option take share
nsclc set maintain buy rate
page analyst certif import disclosur
drugev typetimingopdivo/yervoy/chemofirst data nsclc part dose monotherapi trial bc ocearli rcc intermediate- decis uphold ip valididti ipr data sclc data sclc mainten head data chemoph upcom catalyst biopharmaceut
risk risk rate estim price target includ larger anticip
impact competit pressur hep space impact loe product
reyataz sustiva neg readout
setback clinic pipelin increas pressur price brand product
price debat continu competit pressur io space
page analyst certif import disclosur
page analyst certif import disclosur
estim mm estim total total factset guggenheim secur llc estimatesguggenheim secur llc bristol-my squibb million except per-shar geographyunit good royalti share productsgross incom interest incom allianc incom incom incom incom expens tax interest debt interest expense/dividend attribut unvest net net inform dilut share share dilut dilut compani document guggenheim secur llc estim
 maintain buy rate base posit
outlook keytruda sale
mrk manag recent competitor confer state anticip growth top
bottom line focus oncolog platform includ lynparza
partner azn gardasil vaccin importantli keytruda
believ platform particularli keytruda sale back nsclc monotherapi
increasingli combin includ patient provid counteract
tailwind remnant patent expir zetia vytorin
expect headwind zepati zostovax besid keytruda potenti
product individu mechan action clinic late preclin stage
beyond oncolog believ steglatro ertugliflozin approv late adult
may enter market earli monotherapi well combin
januvia steglujan metformin segluromet believ steglujan could possibl
mitig loe januvia mention share howev
may depend cardiovascular outcom studi hypothes posit
consid cv benefit may class effect note steglatro
monotherapi enter crowd market azn play field
clearli mrk linchpin earlier-than-anticip posit readout
believ posit result bolster keytruda sale low especi
neg patient popul seen posit uptak base
proprietari survey result also bolster success resubmiss
europ futur sinc design exactli way expect
mo mpf number somewhat similar term hazard ratio one could
expect os hr highli signific like see
previou note announc support hypothesi may exist
differ blockad lung cancer see previou note
differ vs blockad import consid case
io plu chemotherapi combin trial agre
initi mpf data posit expect hypothes may
clinic less relev compar inhibit reiter
viewpoint os benefit seen posit like less robust comparison
readout upcom medic meet crucial
compar keytruda tecentriq final put investor concern roch
rhhbi ahead rest sinc could start market base label
soon detail posit result larg ph trial publish matter
fact mrk roger perlmutt state recent competitor confer data
come studi ident keynot immedi
label consist label data becom avail becom
part use explain provid payer patient exactli
keytruda capabl immedi would put data discuss
appropri audienc consist label cost factor
consid assum tecentriq plu avastin chemotherapi
expens keytruda plu chemotherapi rhhbi tripl combin also show
less favor safeti profil compar mrk doubl combin
page analyst certif import disclosur
given promis os data well posit data believ strong
os benefit remind compris one treatment arm opdivo plu
chemotherapi pressur merck may come high express
keytruda monotherapi show mpf month opdivo plu
yervoy show initi mpf month posit patient mpf
reach high express result suggest opdivo plu yervoy might
clinic superior keytruda monotherapi could expect biolog
question remain good os benefit opdivo plu yervoy
express assum cutoff could take market share
keytruda plu chemotherapi segment staunch believ neither
patient physician want use chemotherapi opdivo plu yervoy show suffici
efficaci unfortun detail enough preliminari data
believ io combin could come close enough io plu chemotherapi
combin point unsur io combin may better io
chemotherapi combin neg patient clear cellular rational
support notion howev point evalu opdivo plu
chemotherapi all-com patient popul assum similar
base posit trial outcom pacif overal posit comment
medic literatur suppos azn may receiv approv nsclc howev would
like point patient somewhat preselect trial gener present
nich patient popul compar trial mention
much broader scope understand broader medic commun
support pacif emphas critic voic rais
beyond expect data near-term keytruda plu chemotherapi
squ nsclc addit data head neck cancer keytruda well
keytruda monotherapi nsclc furthermor recent approv
lynparza breast cancer previous treat chemotherapi
neoadjuv adjuv metastat set came one month ahead
pdufa lynparza clearli asset interest us especi potenti compat
keytruda
uniqu posit keytruda approv msi-h believ medic
commun start pay attent indic evidenc recent
public nejm recent approv novemb
foundationon cdx test propos coverag may substanti increas
keytruda footprint pan-tumor indic note tesaro investig
clinic efficaci respect antibodi dmmr/msi-h cancer well
could result competit futur
take remark acceler approv uptak keytruda
nsclc regardless express consider sale
estim keytruda
page analyst certif import disclosur
sourc compani report bloomberg intellig
made adjust model base chang revenu estim driven
script trend key product margin lower estim tax rate
subsequ year result recent tax reform note
provid commentari surround effect tax reform earn call
adjust revenu estim stay rel flat
revenu estim remain
respect ep estim remain
subsequ year ep estim increas
valuat risk
valuat valuat methodolog base dcf analysi believ best
captur overal valu busi merck dcf take present
valu cash flow within forecast window thereaft wind exist
product busi includ risk-adjust contribut pipelin asset use
lt growth rate wacc translat dcf valu price target
current trade ep estim
estim revenu approxim
risk risk rate valuat includ setback key pipelin asset high
competit market competitor bristol-my roch
rhhbi similar compound ident therapeut area hcv competit
increas spend clinic trial particularli line extens keytruda
page analyst certif import disclosur
drugev typetimingkeytruda/chemoresult posit top-line publish upcom medic meet mayb data data squ orr data reg ph data metastat cast -re prostat cancer data ph trial rcc os data decis stage data ph portion topacio tnbc oc eu approv mainten ovarian cancer upcom catalyst biopharmaceut
page analyst certif import disclosur
estim mm estim total total factset guggenheim secur llc estimatesguggenheim secur llc merck co guggenheimincom million except per-shar figur marjunsepdecrevenu expens cog inc keytruda royalti incom income/expens total incom expens loss incom tax incom attribut non-controlling incom net inform dilut share share dilut dilut ep non-gaap inc sourc compani report guggenheim secur llc
catalyst-rich tumor pierc spear
impress pfe turnaround capac output focu certain
therapeut area name immune-oncolog inflamm immunolog vaccin
well bucket rare diseas howev note except rare
diseas enter crowd market pipelin product particular evid
io inhibitor parp inhibitor except pfe inhibitor
ibranc continu gener strong growth lli anticip verzenio approv
base could add competit ibranc
believ immune-oncolog area greatest interest compani
antibodi bavencio crucial backbon monotherapi particular combin
therapi dire need leverag development degre alreadi
approv io platform counteract compani project neg impact
per year recent approv
steglujan may bring revenu note space
crowd alreadi see breakthrough design bavencio plu inlyta
rcc posit note competitor move opdivo plu yervoy
combin rcc see pdufa date april broader term
exampl illustr head start barrier entri built term
io besid timelin hurdl io hurdl race believ fundament
question face particularli recent rhhbi data
readout whether inhibitor bavencio carri main respons
io platform believ efficaci differ inhibit
also note bavencio plu inlyta combin trial may work except well
rcc kidney oxygen sens organ per se mayb limit read-through
indic furthermor believ differ vs
appar vs set confid bavencio recent updat
studi protocol javelin lung evalu bavencio nsclc trial
includ experiment arm approxim patient random
arm arm g/kg bavencio arm platinum-bas chemotherapi arm
 bavencio g/kg everi week week g/kg stratifi nsclc
histolog baselin tumor express level know pfizer
reason behind updat trial design believ like manag want
bolster likelihood clinic success due concern surround inhibit
point right mindset regard futur direct io given
interest cellecti off-the-shelf car-t initi ph studi use bi-
function t-cell engag antibodi r/r myeloma last year howev see
ripe fruit next gener io drug long-term futur unequivoc
question remain gener growth beyond given barrier erect
io space could get better foothold io space
piecem action potenti great leap forward opinion possibl
acquisit see section could solv io troubl one stroke
believ potenti acquisit could occur data readout checkmate-
page analyst certif import disclosur
remind earn call ceo ian read state tax
reform continu look acquisit base valu creation sharehold
alway done specul io develop
obvious io interest categori lot variabl right
perform differ product cfo frank damelio also spoke potenti deal size
recent healthcar confer state think one said agnost
size still lot capac balanc sheet right know
still signific capac rais debt say frank
think big deal would structur depend
size deal depend tax reform could cash would combin
cash equiti still realli strong balanc sheet gener lot
oper cash flow last year still lot capac borrow money
reason rate one thing would say one privileg
cfo pretti much abil deal almost size within
taken togeth believ potenti deal io sphere possibl due
biolog clinic trial result cash balanc tax reform right strateg
earn much higher could possibl highest revenu growth
rate among peer
sourc compani report bloomberg intellig
page analyst certif import disclosur
drugev typetimingbavencio/plddata ph javelin ovarian platinum r/r data ph javelin lung biosimilarptab decis follow ipr roch avastin mf ph prosper pc top-line releas efficaci data ph trial rcc ulcer data ph trial triplet complet part ph pearl data breast ph javelin ovarian ph javelin lung ph javelin bladder upcom catalyst
made adjust model base chang revenu estim driven
script trend key product move estim market entri
talazoparib previous base expect file timelin
recent provid compani manag adjust revenu estim
stay rel flat human health
human health revenu estim move
respect ep estim remain
subsequ year ep estim margin increas
valuat risk
valuat fair valu estim base discount cash
flow analysi impli price-to-earnings multipl earn estim assum
unchang termin growth rate wacc revenu model assum
gener competit includ pfe valuabl pipelin asset
perspect predominantli ph risk-adjust basi
downsid risk risk rate estim valuat includ higher-than-
anticip oper expens new product launch perform wors
expect lead lower profit pipelin setback may alter futur revenu
assumpt push back launch date increas competit gip voc
landscap particularli oncolog may slow initi demand new product
price new brand product
upsid risk risk upsid includ favor clinic data readout new
product commerci regulatori legal chang favor product
page analyst certif import disclosur
